Navigation Links
GeoVax Labs, Inc. Provides Third Quarter 2009 Financial Results and Operational Update
Date:11/6/2009

ATLANTA, Nov. 6 /PRNewswire-FirstCall/ -- GeoVax Labs, Inc. (OTC Bulletin Board: GOVX) ("GeoVax" or "the Company"), an Atlanta-based, biopharmaceutical company developing human vaccines for diseases caused by HIV-1 (Human Immunodeficiency Virus) and other infectious agents, today announced its third quarter 2009 financial results and provided an operational update.

Robert McNally, Ph.D., President and Chief Executive Officer commented, "We are pleased with our progress during the third quarter of 2009 on several fronts. Enrollment for our Phase 2a preventative trial being conducted by the HVTN is proceeding according to plan. We are looking forward to a pre-IND meeting with the FDA later this year to discuss our plans for a Phase 1 therapeutic trial in early 2010. With a modest cash burn rate, continuing support from the HVTN, our IPCAVD grant from the NIH and with our common stock purchase agreement with Fusion Capital in place, our finances are in order to take us into 2011. As we move forward, we believe we will be in a strong position to seek additional government and private support for advancing both our preventative and therapeutic vaccines through Phase 2b and Phase 3 clinical trials."

"These are exciting times for GeoVax and everyone involved in HIV/AIDS vaccine development," Dr. McNally continued. "The recently announced success of a Thailand-based Phase 3 trial for an HIV/AIDS vaccine candidate owned by Sanofi-Aventis and Global Solutions for Infectious Diseases is encouraging to us all and has brought renewed interest to the field. At GeoVax, we have always been confident in our ability to develop an effective vaccine and this recent news has shown that a vaccine is indeed possible."

Review of Financial Results

The Company recorded a net loss of $230,815 for the three months ended September 30, 2009, compared to $722,108 for the same period in 2008. For the nine months ended Septem
'/>"/>

SOURCE GeoVax Labs, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. GeoVax Labs, Inc. Announces Results of 2009 Annual Shareholders Meeting
2. Chuck Panozzo, Founder of Rock Band Styx, Joins GeoVax Labs, Inc. as an Advocate for Its HIV/AIDS Vaccine
3. GeoVax Starts Injections for Phase 2a Human HIV/AIDS Vaccine Trial in USA
4. GeoVaxs Phase 2a HIV/AIDS Vaccine Human Trials to Begin in North and South America
5. GeoVax Reports Progress on Its AIDS Vaccine Technology
6. GeoVax Secures $10 Million Financing Commitment
7. GeoVax Labs, Inc. Reports Fourth Quarter and Year-End 2007 Financial Results
8. GeoVax Vaccine Only 5th AIDS Vaccine Moving to Phase 2 Human Trials
9. Dr. Harriet Robinson Joins GeoVax Team as V.P. of R & D to Accelerate AIDS Vaccine Trials Program
10. GeoVax Labs, Inc. Selected by Georgia Bio as 2008 Deal of the Year Award Winner in Life Sciences Industry
11. GeoVax Labs, Inc. Selects Financial Relations Board as Investor Relations Counsel

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/20/2009)... , PLYMOUTH MEETING, Pa., Nov. 20 /PRNewswire...Times article that questions why currently availa... cancers are being ignored, ECRI Institute, an ind...dmap to the evidence on Finasteride for Preventio...he November 13, 2009, New York Times article, " ...
(Date:11/19/2009)... , ARDEE, Ireland, Nov. 19 Warn...he pricing of its previously announced secondary o...price to the public of $22.25 per share. The sell...n Capital Partners, DLJ Merchant Banking, J.P. Mor...H. Lee Partners, L.P., certain other institutional...
(Date:11/19/2009)... , TAINAN, Taiwan, Nov. 19 /PRNewswire-Asi...ive pharmaceutical ingredients (APIs), announced t...mpound Safety Certification from,SafeBridge(R) Con...rm,s,competency and proficiency in the safe handli...Is), and applies to specific laboratories and,prod...
Breaking Medicine Technology:ECRI Institute Releases Roadmap to the Evidence on Finasteride for Prevention of Prostate Cancer: New Hotline Report to Aid Healthcare Decision Makers and Journalists 2ECRI Institute Releases Roadmap to the Evidence on Finasteride for Prevention of Prostate Cancer: New Hotline Report to Aid Healthcare Decision Makers and Journalists 3Warner Chilcott Prices Secondary Equity Offering 2Warner Chilcott Prices Secondary Equity Offering 3Warner Chilcott Prices Secondary Equity Offering 4ScinoPharm Announces SafeBridge Potent Compound Safety Certification 2Harold Hank Gardner M D Named in the Future Health 100 56303 1Harold Hank Gardner M D Named in the Future Health 100 56303 2Pharmacists Urge the Public to Begin Getting Immunized 56298 1Pharmacists Urge the Public to Begin Getting Immunized 56298 2Pharmacists Urge the Public to Begin Getting Immunized 56298 3Stand Up for Health Care 21 A Labor Day Message From RWDSU President Stuart Appelbaum 56294 1Stand Up for Health Care 21 A Labor Day Message From RWDSU President Stuart Appelbaum 56294 2Stand Up for Health Care 21 A Labor Day Message From RWDSU President Stuart Appelbaum 56294 3
...ive Phase 2a Trial, WALTHAM, Mass., June 12 Repl...that based on feedback from the Food and,Drug Admi...2b clinical,trial of RG2417, an oral formulation o... this year. This will be a multi-center, parallel ...proximately 150 patients with,bipolar disorder wil...
...vement in disease activity through three yea...crease in adverse events, malignancies, infections... over time -, ROCKVILLE, Md., June 12 Human Geno... the presentation of results,from a long- term Pha...R),(belimumab) was associated with sustained impro...
Other Medicine Technology:Repligen Announces Plans to Initiate a Phase 2b Trial for RG2417 in Bipolar Disorder 2Repligen Announces Plans to Initiate a Phase 2b Trial for RG2417 in Bipolar Disorder 3Repligen Announces Plans to Initiate a Phase 2b Trial for RG2417 in Bipolar Disorder 4Repligen Announces Plans to Initiate a Phase 2b Trial for RG2417 in Bipolar Disorder 5Human Genome Sciences Reports Positive Long-Term Data for LymphoStat-B in Patients With Active Systemic Lupus Erythematosus 2Human Genome Sciences Reports Positive Long-Term Data for LymphoStat-B in Patients With Active Systemic Lupus Erythematosus 3Human Genome Sciences Reports Positive Long-Term Data for LymphoStat-B in Patients With Active Systemic Lupus Erythematosus 4Human Genome Sciences Reports Positive Long-Term Data for LymphoStat-B in Patients With Active Systemic Lupus Erythematosus 5Human Genome Sciences Reports Positive Long-Term Data for LymphoStat-B in Patients With Active Systemic Lupus Erythematosus 6Human Genome Sciences Reports Positive Long-Term Data for LymphoStat-B in Patients With Active Systemic Lupus Erythematosus 7
(Date:11/20/2009)..., , NEW YORK, Nov. 20 Re...h report is available in its catalogue. ,, Onc...t Forecast to 2013 ,, http://www.reportlinke...chmarks-and-Market-Forecast-to-2013.html#utm_sourc...newswire ,, Comprehensive Forecasts and Detai...
(Date:11/20/2009)..., , NEW YORK, Nov. 20 Re...h report is available in its catalogue. ,, Ima...ttp://www.reportlinker.com/p0164325/Imaging-Agents...swire&utm_medium=pr&utm_campaign=prnewswir...nized the visualization of organs within the human...
(Date:11/20/2009)..., , HINESBURG, Vt., Nov. 20 K...mpany that specializes in creating sophisticated m...ay announced the launch www.infectioncontrolsourc...care administrators with a comprehensive database ..., "Our mission at Kestrel is to educate healthcar...
(Date:11/20/2009)..., , LOS ANGELES, Nov. 20 As...al feasts, more than 1.25 million people in Los An...rstand the magnitude of the problem, that,s nearly..., people you see every day are hungry - and the si...continues to increase. ,, The Jewish Federatio...
(Date:11/20/2009)...y molecule identified by researchers , ,...may be moving closer to better treatments for bovi...cow disease, and the related condition called Creu...can-1 is crucial to the development of mad cow dis...erstanding its role could help scientists figure o...
Breaking Medicine News(10 mins):Health News:Reportlinker Adds Oncology Roadmap: Brand Spending Benchmarks and Market Forecast to 2013 2Health News:Reportlinker Adds Oncology Roadmap: Brand Spending Benchmarks and Market Forecast to 2013 3Health News:Reportlinker Adds Imaging Agents - A Worldwide Market Review 2Health News:Reportlinker Adds Imaging Agents - A Worldwide Market Review 3Health News:Reportlinker Adds Imaging Agents - A Worldwide Market Review 4Health News:Reportlinker Adds Imaging Agents - A Worldwide Market Review 5Health News:Reportlinker Adds Imaging Agents - A Worldwide Market Review 6Health News:Reportlinker Adds Imaging Agents - A Worldwide Market Review 7Health News:Reportlinker Adds Imaging Agents - A Worldwide Market Review 8Health News:Reportlinker Adds Imaging Agents - A Worldwide Market Review 9Health News:Infection Prevention Online Community Site Launches - Focused on Product Selection 2Health News:The Jewish Federation Unveils Blueprint to End Hunger in Los Angeles 2Health News:The Jewish Federation Unveils Blueprint to End Hunger in Los Angeles 3
...ief that infants' brains don't divide into left-br...study finds the brain's left hemisphere plays the ... beginning almost immediately after birth. Rese...e fMRI has been used to study infants. It is a non...
...osed among men in the United States -- affecting n... treatment options, but new research shows there m... Doctors hope that the drug -- finasteride -- wil... conversion to DHT -- a more active form of the ho...
...ugs used for acute asthma attacks might be causing... studied the use of bronchodilators known as beta-...ry treatment used to relieve acute asthma attacks.... Whatever the mode of administration, they work by...
... blood pressure and heart failure may also benefit...er risk for heart attacks and stroke. Researcher...women from the Heart Outcomes Prevention Evaluatio...ng stroke, peripheral arterial disease, or diabete...
...he risk of dementia , some find light to moderate ... others still find no association at all. In a ... between the ages of 65 and 79 who were followed o...ltogether were both about twice as likely as those...
...ely low body fat whether due to strenuous exercise...from treatment with the appetite-and-weight-regula...ptin may be useful in treating some instances of i...g how much energy is available to the body for imp...
Other Medicine News:Health News:fMRI Offers Insight Into An Infants Brain 2
...oratories is a national reference laboratory and a...h and development. ARUP offers an extensive test m...clinical and anatomic pathology. Owned by the Univ... more than half of the nation's university teachin...
...oratories is a national reference laboratory and a...h and development. ARUP offers an extensive test m...clinical and anatomic pathology. Owned by the Univ... more than half of the nation's university teachin...
...oratories is a national reference laboratory and a...h and development. ARUP offers an extensive test m...clinical and anatomic pathology. Owned by the Univ... more than half of the nation's university teachin...
...oratories is a national reference laboratory and a...h and development. ARUP offers an extensive test m...clinical and anatomic pathology. Owned by the Univ... more than half of the nation's university teachin...
Medicine Products: